Breaking News

Concert Achieves Avanir Milestone

Initiates Phase II trial of AVP-786 in major depressive disorder

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Concert Pharmaceuticals has achieved a $2 million milestone under its development and license agreement with Avanir Pharmaceuticals for the clinical progression of AVP-786. Avanir initiated dosing in a Phase II trial for the adjunctive treatment of major depressive disorder.   Avanir has worldwide rights to develop and commercialize AVP-786 and other deuterium-modified dextromethorphan (d-DM) compounds, which also have potential to treat neurological and psychiatric disorders.   Concert is eligi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters